Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by joint inflammation and cartilage destruction. The symptoms of RA are generally typified by repeating cycles of exacerbation and remission. The induction of clinical remission has been the primary focus of RA treatment in recent years. Clinical remission is facilitated by biological agents such as infliximab, etanercept, adalimumab, tocilizumab, early diagnosis, and management. However, further studies are required to identify novel approaches for drug-free remission. Initial studies on the induction of drug-free remission have been conducted with several agents including infliximab [1] and adalimumab [2] . For example, a previous report has shown that 56/102 (55%) RA patients, who achieved low disease activity using infliximab, were able to discontinue infliximab for over a year without progression of radiological articular destruction [1] . Thus, the development of new treatment strategies is required to improve the rate of complete remission.
Fingolimod or FTY720, is a novel immunosuppressant discovered by Fujita et al.; it is a synthetic structural analogue of myriocin (ISP-I), a compound derived from Isaria sinclairii [3, 4] . In September 2010, FTY720 was approved by the United States Food and Drug Administration for the treatment of relapsing remitting multiple sclerosis. FTY720 has been reported to be effective in several immunological disease models, including multiple sclerosis [5] , myasthenia gravis [6] , atopic dermatitis [7, 8] , and type 1 diabetes mellitus [9, 10] . The unique mode of action of FTY720 differs from that of established immunosuppressants, such as tacrolimus hydrate and cyclosporine; FTY720 is converted in vivo by sphingosine kinase 2 to FTY720 monophosphate (FTY720-P), which is the active form of the drug. FTY720-P acts as a highaffinity agonist of four sphingosine 1-phosphate receptors (S1P 1 , S1P 3 , S1P 4 , and S1P 5 ) [11] ; FTY720-P induces long-term down-regulation of S1P 1 in lymphocytes and suppresses immune responses by sequestering circulating mature lymphocytes from blood and peripheral tissues to secondary lymphoid tissues and the thymus [12, 13] . Combination treatment with FTY720 plus pathogenic antigens, such as glucose-6-phosphate isomerase peptide (GPI [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] ), efficiently suppresses symptom progression of GPI 325-339 -induced arthritis, an animal model of RA, by inducing clonal deletion and anergy of pathogenic T cells as well as immune suppression via regulatory T (Treg) cells [14] .
In the present study, we examined whether combination treatment with FTY720 plus pathogenic antigens would enable remission maintenance using the GPI 325-339 -induced arthritis mouse model.
Results
Combination treatment with FTY720 plus GPI 325-339 suppresses relapse following resensitization
In order to effect complete remission of an autoimmune disease, it is necessary to suppress the immune response as well as maintain the immunosuppressed state. To examine the effect of combination treatment with FTY720 plus GPI 325-339 on remission maintenance, mice treated with FTY720 alone, GPI 325-339 alone, or the FTY720 plus GPI 325-339 combination, were resensitized with GPI 325-339 at day 32 after the first immunization in order to induce a relapse (Fig. 1) . Changes in clinical symptoms were determined based on appearance. Severe or moderate relapse occurred following resensitization in all animals of the placebo, FTY720 alone, and GPI 325-339 alone groups (Fig. 2A) ; relapse was still apparent at day 42-43 after the first immunization, although more prolonged observation is required. In contrast, combination treatment with FTY720 plus GPI 325-339 efficiently suppressed relapse following resensitization in all animals (n ¼ 5); only low intensity symptoms were observed ( Fig. 2A) . In addition, synovial hyperplasia and lymphocyte infiltration were mild or absent in the combination treatment group (Fig. 2B) . Although no significant difference was apparent between the histological scores of the FTY720 plus GPI 325-339 and GPI 325-339 alone groups, 3/5 mice in the GPI 325-339 alone group (with a histological score of 2.0-2.5; Fig. 2B ), exhibited a moderate relapse ( Fig. 2A) . The histological scores correlated with the clinical scores at days 42-43 after the first immunization (P < 0.05, Pearson's correlation coefficient test).
Combination treatment affects pathogenic T cells but not anti-GPI 325-339 antibodies
Schubert et al. [15] previously demonstrated that depletion of CD4 þ cells by treatment with anti-CD4 monoclonal antibody (mAb) prevented GPI-induced arthritis. In addition, it has been reported that adoptive transfer of purified immunoglobulin G (IgG) from GPI-induced arthritis mice failed to Figure 1 . Study timeline DBA/1 mice were immunized with GPI 325-339 on day 0. GPI 325-339 -induced arthritis mice were treated from the day of arthritis onset (days 9-10) to days 13-14. In some experiments, mice were resensitized with GPI 325-339 on day 32. Clinical symptom evaluation and antibody titer measurements were performed on days 0-42 or 43 and 42-43, respectively. [20] . Therefore, in order to examine whether the Treg cells increased by FTY720 treatment are nTreg or iTreg cells, the proportion of Helios-expressing Treg cells in inguinal LNs was determined by flow cytometry. Helios, also known as Ikaros family zinc finger 2, is a known specific marker for thymic-derived Treg (nTreg) cells [21] . No significant difference was observed between the percentage Figure 3 . Anti-GPI 325-339 antibodies might not constitute an important trigger of arthritis relapse. GPI 325-339 -induced arthritis mice were treated with FTY720 alone, GPI 325-339 alone, or the FTY720 plus GPI 325-339 combination. At day 32 after the first immunization, mice were resensitized with hGPI [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] . At days 42-43 after the first immunization, peripheral blood samples were collected and anti-(A) human or (B) mouse GPI 325-339 total IgG antibody titers were measured by enzyme-linked immunosorbent assay. The mean for all mice (n ¼ 5) in each group is indicated by the horizontal line. The significance of differences was examined by Duncan's test. No significant differences were found between each of the groups for either anti-human or mouse GPI 325-339 total IgG antibody titers. (Fig. 5B ).
In addition, IL-10 production was significantly higher in
following stimulation with anti-CD3/anti-CD28 coated dynabeads and IL-2 (Fig. 5C ) The results are shown as mean þ SD. The significance of differences was examined by Duncan's test ( Ã denotes P < 0.05).
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IL-10 producing cells were Foxp3 negative. In addition, high expression of CTLA-4 was observed in
þ cells following stimulation (Fig. 5C) . Thus, GITR þ CD25 À CD4 þ cells, which constitute the anergic population, might prevent relapse following resensitization via high level production of IL-10; the GITR þ non-Treg cells that were induced by the combination treatment might play a key role in the establishment of tolerance.
Discussion
In rheumatoid arthritis, induction of antigen-specific tolerance is more desirable than non-antigen specific tolerance, since the former may lead to fewer adverse effects (such as opportunistic infections); however, the causative/ pathogenic antigen is not always clear and relevant antigens show high variability between human patients. Immune tolerance induced by the administration of an antigen is highly specific and is an appealing method for preventing autoimmune diseases. Intravenous or intraperitoneal administration of antigens has been shown to successfully prevent autoimmune diseases in animal models, such as experimental autoimmune encephalomyelitis [22, 23] ; in these studies tolerance was induced as a result of anergy or clonal deletion of antigen-specific T cells [22, 23] . Previously, we reported that administration of the pathogenic antigen, GPI 325-339 , in combination with FTY720 efficiently suppressed the progression of GPI 325-339 -induced arthritis symptoms by induction of: (1) T cell apoptosis; (2) inhibitory molecule (CTLA-4 and programmed death-1) expressing non-Treg cells; and (3) the expansion of Treg cells in inguinal LNs [14] . In this study, we demonstrated that the combination treatment could maintain remission, during which the immunological memory for regulation of pathogenic T cells might be efficiently induced, suggesting the involvement of unknown environmental and anergic mechanism(s) in tolerance maintenance. GITR is overexpressed on CD25 þ CD4 þ Treg cells and plays a key role in the maintenance of immunological selftolerance [17] . Uraushihara et al. [24] þ cells, which possess suppressive activity, requires both robust stimulation and high cell density conditions in LNs. Type 1 regulatory T (Tr1) cells are generally characterized by the production of high levels of IL-10, moderate levels of TGF-b, IFN-g and IL-5, low levels of IL-2, and no IL-4 [27, 28] . Additionally, it has been reported that the surface markers, CD49b and lymphocyte activation gene 3, are stably and selectively coexpressed on human and mouse Tr1 cells [29] . Asnagli et al. [30] reported that collagen type II-specific Tr1 clones, which were expanded in vitro from collagen type II-specific TCR transgenic mice, were characterized by a specific cytokine profile (IL-10 and (4) production of extracellular adenosine [31] . Treg cells failed to suppress the proliferation of CD25 À CD4 þ cells across the membrane, in contrast with the marked suppression observed when the two populations were on the same side of the membrane [32] . These results indicate that Treg cell-mediated suppression is contact dependent. As we have already stated, FTY720 sequesters lymphocytes and creates a highly cellular environment in secondary lymphoid tissues. Thus, FTY720 might provide the conditions required for maximal Treg cell activity in vivo and promote the induction of immune tolerance.
In conclusion, the results of the present study suggest that the combination treatment with FTY720 and a pathogenic antigen efficiently induces complete remission of GPI 325-339 -induced arthritis by induction of a cell population with high suppressive capacity and creating the required conditions for Treg cell activity in vivo. Further studies will be required to establish in detail the mechanism (s) involved in the induction and maintenance of anergy. The combination of FTY720 plus pathogenic antigen might constitute a breakthrough treatment for the induction of complete remission not only in rheumatoid arthritis but also in other autoimmune diseases.
Materials and Methods
Animals and ethics statement DBA/1 mice were purchased from Japan SLC Inc. (Shizuoka, Japan) and bred under specific pathogen-free conditions. The mice were given g-ray-irradiated food (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) and distilled water ad libitum. This study was performed according to a protocol approved by the Institutional Animal Care Committee of Setsunan University (approval number: K15-15). Throughout the experimental procedures, every effort was made to minimize the number of animals used and their suffering.
Drug and peptides
2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diolhydrochloride (fingolimod; FTY720) was kindly provided by Yoshitomi Pharmaceutical Industries, Ltd (current company name: Mitsubishi Tanabe Pharma Corporation, Osaka, Japan). Peptide 325(IWYINCFGCETHAML)339 of human glucose-6-phosphate isomerase (hGPI [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] ) and peptide 325(IWYINCYGCETHALL)339 of mouse GPI (mGPI 325-339 ) were purchased from Eurofins Genomics K. K., (Tokyo, Japan).
Antibodies
Horse-radish peroxidase-conjugated anti-mouse IgG (H þ L chain) polyclonal antibody was purchased from Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan). Violet 500-conjugated anti-mouse CD4 mAb (clone: RM4-5, 1:200), fluorescein isothiocyanate-conjugated anti-mouse GITR mAb (clone: DTA-1, 1:100), phycoerythrin (PE)-conjugated anti-mouse CTLA-4 mAb (clone: UC10-4F10-11, 1:100), and purified anti-mouse CD3e mAb (clone: 145-2C11) were purchased from BD Biosciences (San Jose, CA, USA). Brilliant Violet 421-conjugated anti-mouse Foxp3 mAb (clone: FJK16s, 1:100), allophycocyanin-conjugated anti-mouse CD25 mAb (clone: PC61.5, 1:50), and PE-conjugated anti-mouse major histocompatibility complex Class II (IA/IE) mAb (clone: M5/114.15.2, 1:200) were purchased from eBioscience (San Diego, CA, USA). Allophycocyanin-conjugated antimouse CD39 mAb (clone: Duha59, 1:200), PE-conjugated anti-mouse Helios mAb (clone: 22F6, 1:100), and Alexa647-conjugated anti-mouse IL-10 mAb (clone: JES5-16E3, 1:100) were purchased from BioLegend, Inc. (San Diego, CA, USA).
Induction of GPI 325-339 -induced arthritis DBA/1 mice (7-to 8-week-old males) were immunized by intracutaneous injection of hGPI 325-339 (10 mg) with Freund's complete adjuvant containing Mycobacterium tuberculosis H37Ra (BD Biosciences) at the base of the tail on day 0. Pertussis toxin (200 ng; EMD Chemicals, Inc., Gibbstown, NJ, USA) was injected intraperitoneally on days 0 and 2 post immunization. In some experiments, mice were resensitized by intracutaneous injection of hGPI 325-339 (10 mg) with Freund's incomplete adjuvant (BD Biosciences) in the back on day 32 after the first immunization. The clinical symptoms of arthritis in each limb were examined and graded according to a clinical arthritis score of 0-4, as previously described [33, 34] . The clinical scores of the four limbs were totaled for each mouse, yielding a maximum score of 16.
Treatment schedules
GPI 325-339 -induced arthritis mice were divided into four groups (Placebo, FTY720 alone, GPI 325-339 alone, and FTY720 plus GPI 325-339 ) and treated from the day of arthritis onset (days 9-10) for 5 days. In the placebo group, mice were given water (orally) together with phosphatebuffered saline (intravenous administration; i.v.) every day. In the FTY20 alone group, mice were administered FTY720 in water (1.0 mg/kg, orally) together with phosphatebuffered saline (i.v.) every day. In the GPI 325-339 alone group, mice were administered water (orally) together with hGPI 325-339 (10 mg, i.v.) every day. In the FTY720 plus GPI 325-339 group, mice were administered FTY720 in water (1.0 mg/kg, orally) together with hGPI 325-339 (10 mg, i.v.) every day (Fig. 1) .
Histochemical staining
At days 42-43 after the first immunization, front limb joints were removed and tissues were fixed with 10% buffered formalin solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 2 days. The fixed limbs were defatted with 90% ethanol at 48C for 2 days and decalcified with K-CX (Falma Co., Tokyo, Japan) at 48C for 9 days. Tissues were processed, embedded in paraffin, and cut into 5 mm sections. The sections were stained with hematoxylin-eosin using Mayer's Hematoxylin Solution (Wako Pure Chemical Industries, Ltd.). Synovial hyperplasia and lymphocyte infiltration of joints were histologically graded as follows: 1, normal; 2, mild; 3, moderate; 4, severe (histological score) [34, 35] . The histological score was evaluated blindly by two investigators and mean values were calculated.
Measurement of anti-GPI 325-339 total IgG antibody titer
At days 42-43 after the first immunization, peripheral blood samples were collected for measurement of GPI [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] antibody titer by enzyme-linked immunosorbent assay. 96-well polystyrene microplates were coated with human or mouse GPI 325-339 (1.0 mg/mL) in 0.1 M sodium phosphate buffer (pH 7.5) containing 0.1% NaN 3 (0.1 mL/well) at 48C overnight. Following incubation, the microplates were washed four times with 10 mM sodium phosphate buffer (pH 7.0) containing 0.1 M NaCl (buffer P, 0.25 mL/well). Then, 10 mM sodium phosphate buffer (pH 7.0) containing 0.1 M NaCl, 0.1% bovine serum albumin (BSA, Nacalai Tesque Inc., Kyoto, Japan), and 0.1% NaN 3 (buffer A) was added to the wells (0.25 mL/well) and incubated at 48C for 4 h. Following incubation, buffer A was removed, serum samples previously diluted 10,000-fold with buffer A were added to the wells (0.15 mL/well), and then incubated at 378C for 3 h and 48C overnight. The microplates were then washed as detailed above. Goat (anti-mouse IgG H þ L) Fab'-horse-radish peroxidase-conjugate (Medical and Biological Laboratories Co., Ltd.), previously diluted 7500-fold with buffer P, containing 0.1% BSA was added to the wells (0.15 mL/well) and incubated at 378C for 3 h. Finally, the microplates were washed as described above and incubated with 50 mM sodium acetate buffer (pH 5.0) containing 7.5 mM o-phenylenediamine (Nacalai Tesque Inc.), 0.025% BSA, and 0.025% H 2 O 2 (0.1 mL/well) at 378C for 10-20 min. The enzymatic reaction was terminated by the addition of 1.2 M H 2 SO 4 containing 0.24% Na 2 SO 3 (0.05 mL/well). Absorbance at 490 nm was measured with a plate reader (Model 680, Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Flow cytometry analysis
Cells were obtained from inguinal LNs upon completion of treatment (day 14 after the first immunization) and were hemolyzed with a solution of Tris (hydroxymethyl) aminomethane-buffered ammonium chloride buffer (0.16 M ammonium chloride: 0.17 M Tris ¼ 9:1, pH 7.2). Cells were stained with fluorescence-labeled anti-mouse CD4, GITR, and CD39 mAbs at 48C for 30 min. The cells were fixed and permeabilized using the Foxp3 Fixation/Permeabilization Buffer (eBioscience) and then stained with fluorescence-labeled anti-mouse Foxp3 and Helios mAbs at 48C for 30 min. Flow-cytometric analysis was performed with BD FACS Aria II (BD Biosciences).
Suppression assay
Upon completion of treatment (day 14 after the first immunization), cells were obtained from inguinal LNs of FTY720 plus GPI 325-339 combination-treated mice and hemolyzed as described above. Cells were stained with fluorescence-labeled anti-mouse CD4, IA/IE, GITR, and CD25 mAbs at 48C for 30 2 . After 72 h, violet fluorescence intensity was analyzed with a BD FACS Aria II (BD Biosciences). The proliferation index was analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Stimulation and intracellular staining
Upon completion of treatment (day 14 after the first immunization), GITR À CD25
and GITR þ CD25 À CD4 þ cells from inguinal LNs of the FTY720 plus GPI 325-339 combination-treated mice were purified using a BD FACS Aria II as described above. The cells (5 Â 10 4 cells) were added into a 96-well flat-plate and then activated with Dynabeads 1 Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 50 U/mL recombinant mouse IL-2 (Miltenyi Biotec, Bergisch Gladbach, Germany) at 378C under 5% CO 2 . After 72 h, the cells were restimulated for 5 hours at 378C under 5% CO 2 with phorbol 12-myristate 13-acetate (15 ng/mL) and ionomycin (750 ng/mL) in the presence of GolgiStop (BD Biosciences). The cells were fixed and permeabilized using the BD Pharmingen TM Transcription Factor Buffer Set (BD Biosciences) and then stained with fluorescence-labeled anti-mouse Foxp3, IL-10, and CTLA-4 mAbs at 48C for 30 min. Flow-cytometric analysis was performed with BD FACS Aria II (BD Biosciences).
Statistical analysis
Statistical analysis was carried out using IBM SPSS Statistics Version 22 software. Differences between the groups were compared using by one-way analysis of variance followed by Duncan's test. Pearson's correlation coefficient test was used to determine the correlations; P < 0.05 was considered statistically significant.
